Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient

NCT07649395 is registered in ClinicalTrials.gov with Mei Feng as lead sponsor.

NCT NCT07649395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07649395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient
Lead sponsor
Mei Feng
Phase
Not applicable
Overall status
Completed
Start date
February 1, 2021
Completion date
June 30, 2024
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical squamous cell carcinoma